Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Opko Health Inc (OPK)

Opko Health Inc (OPK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Financial Summary for [[ item.sessionDateDisplayLong ]]
OPKO Health, Inc engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel and Mexico. The Diagnostics segment operates Bio-Reference Laboratories, a clinical facility that offers testing services in the detection, diagnosis, evaluation, monitoring and treatment of diseases. The company's pharmaceutical business features Rayaldee, an FDA-approved treatment for secondary hyperparathyroidism (SHPT) in adults with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency and VARUBI for chemotherapy induced nausea and vomiting. OPKO Health has a development and commercial supply pharmaceutical unit in Ireland along with a global supply chain operation and holding wing. The company also owns specialty active pharmaceutical ingredients (APIs) manufacturer in Israel.

Fiscal Year End Date: 12/31

(Values in U.S. Thousands) Jun, 2024 Mar, 2024 Dec, 2023 Sep, 2023 Jun, 2023
Sales 182,190 173,690 181,910 178,600 265,420
Sales Growth +4.89% -4.52% +1.85% -32.71% +11.72%
Net Income -10,310 -81,840 -66,480 -84,470 -19,640
Net Income Growth +87.40% -23.10% +21.30% -330.09% -7.50%
(Values in U.S. Thousands) Jun, 2024 Mar, 2024 Dec, 2023 Sep, 2023 Jun, 2023
Total Assets 1,979,870 1,974,020 2,011,700 2,056,680 2,158,900
Total Assets Growth +0.30% -1.87% -2.19% -4.73% -0.50%
Total Liabilities 584,550 721,210 622,480 612,110 623,550
Total Liabilities Growth -18.95% +15.86% +1.69% -1.83% +0.92%
(Values in U.S. Thousands) Jun, 2024 Mar, 2024 Dec, 2023 Sep, 2023 Jun, 2023
Operating Cash Flow -62,000 -35,570 -28,200 10,100 -23,010
Operating Cash Flow Growth -74.30% -26.13% -379.21% +143.89% -1.59%
Net Cash Flow -55,310 -20,240 -57,310 -14,570 -45,080
Change in Net Cash Flow -173.27% +64.68% -293.34% +67.68% -6.42%
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar